US Stock Futures Down Ahead Of Industrial Production Report - Cognizant Tech Solns (NASDAQ:CTSH)

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Pre-open moversUS stock futures traded lower in early pre-market trade, ahead of economic data. The Empire State manufacturing index for September will be released at 8:30 a.m. ET, while industrial production data for August will be released at 9:15 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 25 points to 16,881.00, while the Standard & Poor's 500 index futures fell 3.70 points to 1,973.00. Futures for the Nasdaq 100 index dropped 6.25 points to 4,055.75.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

A Peek Into Global Markets European markets were mostly lower today, with the Spanish Ibex Index falling 0.35%, STOXX Europe 600 Index dropping 0.09%. German DAX 30 index rose 0.13%, French CAC 40 Index fell 0.21% and London's FTSE 100 Index dropped 0.22%.In Asian markets, Hong Kong's Hang Seng Index dipped 0.97%, China's Shanghai Composite Index rose 0.31% and India's BSE Sensex tumbled 0.90%.Broker Recommendation

Analysts at Goldman Sachs downgraded Cree (NASDAQ: CREE) from Buy to Neutral. The target price for Cree has been lowered from $60 to $48. Cree's shares tumbled 3.46% to $41.20 in pre-market trading. Breaking news

Mylan (NASDAQ: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. To read the full news, click here.
Cognizant (NASDAQ: CTSH) today announced that it has entered into a definitive agreement to acquire TriZetto Corporation for $2.7 billion in cash, subject to customary adjustments. Based in Englewood, CO, privately-held TriZetto is a leading provider of healthcare IT software and solutions. To read the full news, click here.
Danaher (NYSE: DHR) has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher Corporation or one of its direct or indirect subsidiaries will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2 billion. To read the full news, click here.
TG Therapeutics (NASDAQ: TGTX) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, in combination with Imbruvica® (ibrutinib) for the treatment of Chronic Lymphocytic Leukemia (CLL) in patients with high risk cytogenetics. To read the full news, click here.